Micreos B.V.

Micreos B. V. is a biotechnology company focused on developing engineered endolysins targeting chronic dermatological and oncological conditions, providing innovative solutions for infection management in healthcare. Founded in 2005 in The Hague, Netherlands, Micreos B.

V. specializes in the discovery and development of engineered endolysins. The company has undergone strategic pivots but remains focused on its core technology. The firm was founded by Mark Offerhaus, who has a history of entrepreneurial ventures, and it operates under the leadership of CEO Floor Dessing-Pietersma.

Micreos has raised EUR 25 million in its most recent Growth funding round on October 25, 2022, bringing the total amount raised to EUR 25 million across 7 deals. Micreos Pharmaceuticals AG focuses on engineered endolysins, recombinant proteins that target harmful pathogens such as Staphylococcus aureus (S. aureus), particularly beneficial for patients with Atopic Dermatitis (AD) and Cutaneous T-cell Lymphoma (CTCL). Their products aim to eliminate S.

aureus colonization while preserving the beneficial microbiome, serving healthcare providers across Europe and North America with innovative therapeutic solutions designed for chronic conditions. For the most recent year, 2014, Micreos reported a revenue of EUR 3,129,084. 10. The company’s financial performance for 2022 indicated an EBITDA loss of EUR 27,939,370.

10, reflecting ongoing investment in its development efforts. In October 2022, Micreos B. V. secured EUR 25 million in growth funding to advance its endolysin technology platform, aiming to replace antibiotics in various medical applications.

The company plans to develop new products and expand its offerings into additional markets, leveraging this funding to support these initiatives. Specific regions targeted for expansion include further penetration in the North American market, with plans to launch new product lines in 2023.